Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 13.75B 12.05B 11.11B 10.29B 19.51B 1,305B 19.86B 133B 51.77B 644B 51.61B 50.49B 2,229B P/E 2026 *
-23.2x
P/E 2027 * -65.9x
Enterprise Value 13.49B 11.83B 10.9B 10.1B 19.15B 1,281B 19.49B 131B 50.82B 632B 50.66B 49.56B 2,188B EV / Sales 2026 *
15.1x
EV / Sales 2027 * 9.09x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day+3.79%
1 week+8.88%
Current month+8.88%
1 month+17.39%
3 months+16.84%
6 months+3.80%
Current year+9.13%
1 week 77.95
Extreme 77.95
86.67
1 month 72.3
Extreme 72.3
86.67
Current year 68.9
Extreme 68.9
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-25Fiscal year

Chief Operating Officer

78,000 0.0472%
06-25Sell

General Counsel

-3,069 0.0019%
06-25Fiscal year

Founder

150,000 0.0908%
Change 5-day change 1-year change 3-year change Capi.($)
+3.79%+8.88%+106.63%+106.63% 13.75B
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
+1.10%+7.77%+28.18%-3.96% 34.38B
-0.16%+8.42%+28.20%+63.00% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+0.32%+1.09%+13.28%+21.98% 13.71B
-1.63%+52.22%+1,703.70%+719.12% 12.69B
Average +0.03%+8.75%+264.31%+189.30% 25.87B
Weighted average by Cap. +0.01%+6.58%+180.04%+171.58%

Financials

2026 *2027 *
Net sales 893M 783M 722M 669M 1.27B 84.82B 1.29B 8.66B 3.36B 41.83B 3.35B 3.28B 145B 1.5B 1.32B 1.21B 1.12B 2.13B 143B 2.17B 14.56B 5.66B 70.36B 5.64B 5.52B 244B
Net income -595M -522M -481M -446M -845M -56.54B -860M -5.77B -2.24B -27.88B -2.24B -2.19B -96.53B -199M -174M -160M -149M -282M -18.85B -287M -1.92B -748M -9.3B -745M -729M -32.19B
Net Debt -252M -221M -204M -189M -358M -23.98B -365M -2.45B -951M -11.82B -948M -927M -40.93B -88.41M -77.51M -71.43M -66.18M -125M -8.39B -128M -857M -333M -4.14B -332M -325M -14.33B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-06 US$83.18 +1.69% 1,847,437
26-07-02 US$81.80 +3.30% 2,301,899
26-07-01 US$79.19 -0.13% 1,442,398
26-06-30 US$79.29 -1.74% 2,380,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
83.18USD
Average target price
104.86USD
Spread / Average Target
+26.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock